Nurix Therapeutics, a pharmaceutical company based in the United States, specializes in developing innovative oral, small molecule therapies to target cellular protein levels for cancer and immune disorders. With a focus on ESG principles, Nurix's pipeline includes protein degraders for BTK and E3 ligase inhibitors for T cell activation regulation. Their drug candidates, NX-2127 and NX-1607, offer novel treatment approaches for B-cell malignancies and immuno-oncology indications. With a high-risk rating score of 32.3, Nurix Therapeutics is dedicated to revolutionizing the pharmaceutical industry through cutting-edge research and development.